Metraipolis › archive › dc_ab7bc83f9f76
Additive toxicity arising from combined use of immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with renal or endometrial carcinoma:… — Europe PMC PMID:38779442
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/38779442
- DOI
- 10.1016/j.mex.2024.102730
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-07T23:20:31.233Z
- SHA-256 of the archived text
d6c8a81dfe6af08ad0f932c8e42f29c33028c344c702c1a5ac3e21a8b8d45692- Stable URL of this page
https://metraipolis.com/documento/dc_ab7bc83f9f76
How to cite
Additive toxicity arising from combined use of immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with renal or endometrial carcinoma:… — Europe PMC PMID:38779442 — Europe PMC (en), https://europepmc.org/article/MED/38779442 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ab7bc83f9f76 (Metraipolis archive dc_ab7bc83f9f76, sha256 d6c8a81dfe6af08ad0f932c8e42f29c33028c344c702c1a5ac3e21a8b8d45692)
BibTeX
@misc{dcab7bc83f9f76,
title = {Additive toxicity arising from combined use of immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with renal or endometrial carcinoma:… — Europe PMC PMID:38779442},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/38779442},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ab7bc83f9f76; sha256 d6c8a81dfe6af08ad0f932c8e42f29c33028c344c702c1a5ac3e21a8b8d45692},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/38779442. Agents can read the archived copy with the MCP tool read_document.